Center for Drug Evaluation and Research, U.S. Food and Drug Administration, Silver Spring, Maryland.
Oncology Center of Excellence, U.S. Food and Drug Administration, Silver Spring, Maryland.
Clin Cancer Res. 2024 Aug 15;30(16):3371-3377. doi: 10.1158/1078-0432.CCR-24-0517.
On September 2, 2022, the Food and Drug Administration (FDA) approved durvalumab in combination with cisplatin and gemcitabine, for the treatment of patients with unresectable or metastatic biliary tract cancers (BTC). On October 31, 2023, the FDA approved pembrolizumab in combination with cisplatin and gemcitabine for the same indication. Approvals were based on two randomized, multiregional, placebo-controlled trials that randomly allocated patients to receive durvalumab (TOPAZ-1) or pembrolizumab (KEYNOTE-966) in combination with chemotherapy or placebo in combination with chemotherapy. Overall survival (OS) was the primary endpoint in both studies. In both studies, a statistically significant and clinically meaningful improvement in OS was demonstrated. In the TOPAZ-1 trial, the median OS of patients receiving durvalumab was 12.8 months [95% confidence interval (CI), 11.1-14.0] and 11.5 months (95% CI, 10.1-12.5) in patients receiving placebo [hazard ratio (HR), 0.80 (95% CI, 0.66-0.97)]. In the KEYNOTE-966 trial, the median OS of patients receiving pembrolizumab was 12.7 months (95% CI, 11.5-13.6) and 10.9 months (95% CI, 9.9-11.6) in patients receiving placebo [HR, 0.83 (95% CI, 0.72-0.95)]. The addition of checkpoint inhibitors to standard of care chemotherapy for this indication did not reveal any new adverse event signals, and the safety profile was generally consistent with the known clinical experience with durvalumab, pembrolizumab, and the backbone chemotherapy regimen. The approvals of durvalumab and pembrolizumab in combination with standard of care cisplatin and gemcitabine for the treatment of unresectable or metastatic BTC add two new therapeutic options for these patients.
2022 年 9 月 2 日,美国食品和药物管理局(FDA)批准度伐利尤单抗联合顺铂和吉西他滨,用于治疗不可切除或转移性胆管癌(BTC)患者。2023 年 10 月 31 日,FDA 批准帕博利珠单抗联合顺铂和吉西他滨用于相同适应证。批准基于两项随机、多区域、安慰剂对照试验,这些试验将患者随机分配接受度伐利尤单抗(TOPAZ-1)或帕博利珠单抗(KEYNOTE-966)联合化疗或安慰剂联合化疗。总生存期(OS)是两项研究的主要终点。在这两项研究中,均显示 OS 有统计学意义和临床意义的改善。在 TOPAZ-1 试验中,接受度伐利尤单抗治疗的患者中位 OS 为 12.8 个月[95%置信区间(CI),11.1-14.0],而接受安慰剂治疗的患者中位 OS 为 11.5 个月[95%CI,10.1-12.5][风险比(HR),0.80(95%CI,0.66-0.97)]。在 KEYNOTE-966 试验中,接受帕博利珠单抗治疗的患者中位 OS 为 12.7 个月[95%CI,11.5-13.6],而接受安慰剂治疗的患者中位 OS 为 10.9 个月[95%CI,9.9-11.6][HR,0.83(95%CI,0.72-0.95)]。在该适应证中,将检查点抑制剂加入标准护理化疗未显示出任何新的不良事件信号,安全性与度伐利尤单抗、帕博利珠单抗和基础化疗方案的已知临床经验大致一致。度伐利尤单抗和帕博利珠单抗联合标准护理顺铂和吉西他滨用于治疗不可切除或转移性 BTC 的批准为这些患者增加了两种新的治疗选择。